Bicara Therapeutics Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BCAX Nasdaq 2834 www.bicara.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bicara Therapeutics Inc.

Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia - Jan 8th, 2025 3:16 pm
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 12th, 2024 12:30 pm
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference - Nov 11th, 2024 9:01 pm
Opening Day: Another trio of biotech IPOs make Friday debut - Oct 14th, 2024 10:45 am
MBX Biosciences earns Buy rating at three investment firms - Oct 8th, 2024 2:44 pm
RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares - Sep 23rd, 2024 11:05 pm
FMR LLC Acquires New Stake in Bicara Therapeutics Inc - Sep 18th, 2024 7:01 pm
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Sep 17th, 2024 1:13 pm
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Sep 16th, 2024 8:01 pm
TPG-backed Bicara Therapeutics raises $315 million in US IPO - Sep 13th, 2024 1:38 am
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering - Sep 13th, 2024 1:15 am
Three biotechs raise $700M in rare burst of IPO activity - Sep 12th, 2024 11:02 pm